Pre‐Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS‐CoV‐2 Inactivated Vaccines
Advanced Science · 2026
DOI: 10.1002/advs.202514147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Chanyuan Ye und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical …. Hauptthemen laut MEDLINE: Th1 Cells, COVID-19 Vaccines, COVID-19, SARS-CoV-2. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Zhejiang Plan for the Special Support for Top-notch Talents in China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Understanding and enhancing vaccine‐induced immune responses in the elderly population is critical, as they face elevated risks of severe COVID‐19. This work systematically delineates age‐associated alterations in innate and adaptive immunity and their impact on responses to SARS‐CoV‐2 inactivated vaccination. Compared to young mice, aged mice exhibited polarized bystander Th1 CD4 + T cell populations (31.68 ± 5.62% versus 3.31 ± 0.48%) with distinct transcriptomic signatures, which augmented humoral immunity in aged mice. In human cohorts, post‐vaccination antigen‐specific antibody titers are comparable across different age groups. Stratified analysis based on antibody concentration reveals that high‐responder individuals possess elevated pre‐existing Th1 cells at baseline, which exhibit a modest positive correlation with post‐vaccination antibody titers (r = 0.423, p = 0.001). Therefore, compared to age‐based stratification, baseline Th1 cells serve as a superior predictive biomarker for antibody generation following SARS‐CoV‐2 inactivated vaccination. Collectively, these findings unveil novel mechanisms underlying Th1‐mediated vaccine immunogenicity, offering pivotal insights for developing next‐generation vaccines with optimized protective efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, 250117, China.
Förderung
- National Key R&D Program of China
- Zhejiang Plan for the Special Support for Top-notch Talents in China
- National Key Research and Development Program of China
Zitieren
APA
Ye, C., Zhang, X., Qiu, L., Ji, J., Gu, J., Jia, H., Lu, Y., Chen, J., Meng, Z., Lian, J., Yao, H., Zeng, X., & Yang, Y. (2026). Pre‐Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS‐CoV‐2 Inactivated Vaccines. Advanced Science. https://doi.org/10.1002/advs.202514147
Vancouver
Ye C, Zhang X, Qiu L, Ji J, Gu J, Jia H, et al. Pre‐Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS‐CoV‐2 Inactivated Vaccines. Advanced Science. 2026. doi:10.1002/advs.202514147
BibTeX
@article{Ye2026,
author = {Ye, Chanyuan and Zhang, Xiaoli and Qiu, Lingfeng and Ji, Jia and Gu, Jueqing and Jia, Hongyu and Lu, Yingfeng and Chen, Jiyang and Meng, Zelu and Lian, Jiangshan and Yao, Hangping and Zeng, Xun and Yang, Yida},
title = {Pre‐Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS‐CoV‐2 Inactivated Vaccines},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202514147}
}
EUVIMED